Hepatitis A Virus Cellular Receptor 2
"Hepatitis A Virus Cellular Receptor 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An Ig domain-containing membrane receptor that is expressed by TH1 CELLS. It regulates the activation of MACROPHAGES and inhibits TH1-mediated auto- and alloimmune responses to promote IMMUNE TOLERANCE.
| Descriptor ID |
D000072597
|
| MeSH Number(s) |
D12.776.395.550.479 D12.776.543.550.437 D12.776.543.750.830.219
|
| Concept/Terms |
Hepatitis A Virus Cellular Receptor 2- Hepatitis A Virus Cellular Receptor 2
- CD366 Antigen
- Antigen, CD366
- T-Cell Immunoglobulin and Mucin Domain-Containing Protein 3
- T Cell Immunoglobulin and Mucin Domain Containing Protein 3
- TIMD3 Protein
- HAVCR2 Protein
- T-Cell Immunoglobulin Mucin Receptor 3
- T Cell Immunoglobulin Mucin Receptor 3
|
Below are MeSH descriptors whose meaning is more general than "Hepatitis A Virus Cellular Receptor 2".
Below are MeSH descriptors whose meaning is more specific than "Hepatitis A Virus Cellular Receptor 2".
This graph shows the total number of publications written about "Hepatitis A Virus Cellular Receptor 2" by people in this website by year, and whether "Hepatitis A Virus Cellular Receptor 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hepatitis A Virus Cellular Receptor 2" by people in Profiles.
-
Peptidoglycan from Bacillus anthracis Inhibits Human Macrophage Efferocytosis in Part by Reducing Cell Surface Expression of MERTK and TIM-3. Immunohorizons. 2024 Mar 01; 8(3):269-280.
-
Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy. Biomolecules. 2021 07 27; 11(8).
-
Check point inhibitors as therapies for infectious diseases. Curr Opin Immunol. 2017 Oct; 48:61-67.
-
Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology. 2014 Feb; 146(2):550-61.